These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 1801688)

  • 1. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
    Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
    Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
    Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
    Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
    Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.
    Wörmann B; Reuter C; Zühlsdorf M; Büchner T; Hiddemann W
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):39-43. PubMed ID: 7801145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen.
    Tafuri A; De Felice L; Petrucci MT; Mascolo MG; Ricciardi MR; Ciliberti C; Martelli MP; Petti MC
    Cytokines Mol Ther; 1995 Dec; 1(4):301-7. PubMed ID: 9384683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects.
    Büchner T; Hiddemann W; Wörmann B; Zühlsdorf M; Rottmann R; Innig G; Maschmeier G; Ludwig WD; Sauerland MC; Heinecke A
    Semin Oncol; 1997 Feb; 24(1):124-31. PubMed ID: 9045298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
    Estrov Z; Estey EH; Andreeff M; Talpaz M; Kurzrock R; Reading CL; Deisseroth AB; Gutterman JU
    Exp Hematol; 1992 Jun; 20(5):558-64. PubMed ID: 1587302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
    Waga K; Furusawa S; Nagashima S; Saito K; Shishido H
    Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
    te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
    Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
    Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
    Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
    N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.
    Thomas X; Raffoux E; Renneville A; Pautas C; de Botton S; Terre C; Gardin C; Hayette S; Preudhomme C; Dombret H
    Cancer; 2010 Apr; 116(7):1725-32. PubMed ID: 20143449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
    Büchner T; Hiddemann W; Koenigsmann M; Zühlsdorf M; Wörmann B; Boeckmann A; Freire EA; Innig G; Maschmeyer G; Ludwig WD
    Blood; 1991 Sep; 78(5):1190-7. PubMed ID: 1878586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte colony-stimulating factor in acute myeloid leukemia.
    Usuki K; Iki S; Endo M; Kitazume K; Ito K; Watanabe M; Urabe A
    Stem Cells; 1995 Nov; 13(6):647-54. PubMed ID: 8590866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
    Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
    Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.